GlassScriptPhysician profile
James Kyle Turnbo
NPI 1750483822
$123,536.65
in general payments reported to CMS, 2019-2025
62 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,510 · 2020: $1,820 · 2021: $16K · 2022: $7,438 · 2023: $37K · 2024: $36K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Food and Beverage: $5,175 · Consulting Fee: $2,250 · Travel and Lodging: $1,536 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $87,700.00 |
| Food and Beverage | $5,175.03 |
| Consulting Fee | $2,250.00 |
| Travel and Lodging | $1,536.09 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $112,971.21 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $1,687.58 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $943.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $765.67 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $765.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $739.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $669.85 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $520.69 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $356.57 | 2019-2024 | Xarelto |
| Allergan, INC. | $322.58 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $303.58 | 2019-2024 | Qelbree, Qelbree |
| Eisai INC. | $228.33 | 2020-2025 | |
| Biogen, INC. | $185.92 | 2021-2022 | |
| Astellas Pharma US INC | $178.95 | 2022-2025 | Veozah |
| Merck Sharp & Dohme LLC | $176.66 | 2019-2023 | Verquvo, Belsomra, Steglatro |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Turnbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.